New Trial to Study Asthma Drug Responses, Genetic Factors in African-Americans | GenomeWeb

NEW YORK (GenomeWeb News) — The National Heart, Lung, and Blood Institute has launched a multi-site clinical trial to assess how African-Americans with asthma respond to different therapies, and to examine the genetics at play in those responses, NHLBI said today.

The Best African American Response to Asthma Drugs (BARD) study will enroll roughly 500 children and adults at 30 sites in 14 states to research their responses to varying combinations of medications and dosages and how genes may affect those responses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.